JP2025038093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025038093A5 JP2025038093A5 JP2024219599A JP2024219599A JP2025038093A5 JP 2025038093 A5 JP2025038093 A5 JP 2025038093A5 JP 2024219599 A JP2024219599 A JP 2024219599A JP 2024219599 A JP2024219599 A JP 2024219599A JP 2025038093 A5 JP2025038093 A5 JP 2025038093A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pge2
- composition
- population
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281064P | 2016-01-20 | 2016-01-20 | |
| US62/281,064 | 2016-01-20 | ||
| US201662402883P | 2016-09-30 | 2016-09-30 | |
| US62/402,883 | 2016-09-30 | ||
| JP2018537803A JP7653759B2 (ja) | 2016-01-20 | 2017-01-20 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| PCT/US2017/014449 WO2017127755A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| JP2023000071A JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000071A Division JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025038093A JP2025038093A (ja) | 2025-03-18 |
| JP2025038093A5 true JP2025038093A5 (https=) | 2025-04-02 |
Family
ID=59362155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537803A Active JP7653759B2 (ja) | 2016-01-20 | 2017-01-20 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023000071A Pending JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024219599A Pending JP2025038093A (ja) | 2016-01-20 | 2024-12-16 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537803A Active JP7653759B2 (ja) | 2016-01-20 | 2017-01-20 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023000071A Pending JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11413309B2 (https=) |
| EP (1) | EP3405568A4 (https=) |
| JP (3) | JP7653759B2 (https=) |
| WO (1) | WO2017127755A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CN109072192B (zh) * | 2016-02-16 | 2024-02-09 | 杜克大学 | 用于扩展和分化生产抗体的b细胞的方法 |
| US11634686B2 (en) | 2016-11-01 | 2023-04-25 | Jian Feng | Method of producing naive pluripotent stem cells |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| EP3595683A1 (en) * | 2017-03-15 | 2020-01-22 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| WO2018183888A2 (en) | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| KR102382431B1 (ko) * | 2017-11-23 | 2022-04-01 | 베이징 이터널 머터리얼 테크놀로지 씨오., 엘티디 | 화합물 및 이를 이용한 유기 전계 발광 소자 |
| US20210015859A1 (en) * | 2017-12-08 | 2021-01-21 | Fate Therapeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CA3083779A1 (en) | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
| KR20210126556A (ko) | 2018-01-25 | 2021-10-20 | 미아 리바이트 | 개선된 면역치료 방법 |
| JP7575271B2 (ja) * | 2018-03-29 | 2024-10-29 | フェイト セラピューティクス，インコーポレイテッド | 操作された免疫エフェクター細胞およびその使用 |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| US20220040230A1 (en) * | 2018-12-11 | 2022-02-10 | The Regents Of The University Of California | Compositions and methods for immunotherapies |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| KR20220004028A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020231882A2 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| JP2022551975A (ja) * | 2019-10-15 | 2022-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｆｃ封鎖を介する移植細胞保護 |
| CN110592016B (zh) * | 2019-10-28 | 2020-10-02 | 上海科医联创生物科技有限公司 | 一种特异性t细胞的培养方法 |
| CN110628717B (zh) * | 2019-10-28 | 2020-10-30 | 上海科医联创生物科技有限公司 | 一种浸润性t细胞的培养方法 |
| BR112022008215A2 (pt) * | 2019-10-31 | 2022-07-12 | Res Inst Nationwide Childrens Hospital | Geração de células nk humanas primárias e expandidas knock-out de cd38 |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| MX2022006725A (es) * | 2019-12-06 | 2022-08-22 | Fate Therapeutics Inc | Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños. |
| EP4087916A1 (en) * | 2020-01-07 | 2022-11-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of producing t cell populations using induced pluripotent stem cells |
| AU2021292695A1 (en) | 2020-06-19 | 2023-02-02 | Fate Therapeutics, Inc. | Combining iPSC-derived effector cell types for immunotherapy use |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| WO2022040504A2 (en) * | 2020-08-21 | 2022-02-24 | Georgetown University | Stem cell-like memory t cells and uses thereof |
| EP4228406A4 (en) | 2020-10-14 | 2024-11-13 | Ossium Health, Inc. | SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION |
| CN117279650A (zh) | 2020-12-18 | 2023-12-22 | 奥瑟姆健康公司 | 细胞治疗方法 |
| CN114763563B (zh) * | 2021-01-12 | 2024-04-30 | 深圳华大临床检验中心 | 一种提高慢病毒感染效率的方法 |
| EP4288069A4 (en) * | 2021-02-07 | 2025-03-12 | Baylor College of Medicine | Engineered nkt cells for expansion and in vivo preservation and methods of use for the control of tumor cells |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| EP4504914A4 (en) | 2022-04-08 | 2026-04-29 | Fate Therapeutics Inc | Cells having solid tumor targeting backbone and use thereof |
| CA3247010A1 (en) | 2022-04-08 | 2023-10-12 | Ono Pharmaceutical Co., Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING |
| WO2024211852A1 (en) * | 2023-04-07 | 2024-10-10 | Fate Therapeutics, Inc. | Ipsc-derived nk cell for lymphoma treatment |
| WO2024243325A2 (en) * | 2023-05-22 | 2024-11-28 | The Board Of Trustees Of The University Of Illinois | Combination of pac-1 and car t-cell treatments |
| CN116904400B (zh) * | 2023-09-12 | 2023-12-01 | 成都以邦医药科技有限公司 | 可利霉素在体外car/tcr-t细胞产品制备过程优化中的应用 |
| WO2025217183A1 (en) * | 2024-04-09 | 2025-10-16 | Board Of Regents, The University Of Texas System | Prepared natural killer cells and uses thereof |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92382A (en) | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| AU770867B2 (en) | 1999-08-13 | 2004-03-04 | Fumie Sato | Prostaglandin derivatives |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040175373A1 (en) | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| WO2007103901A2 (en) | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| EP2094837B1 (en) | 2006-12-14 | 2012-04-25 | Medical Research Council | Use of pi3k, m-tor and akt inhibitors to induce foxp3 expression and generate regulatory t cells |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| EP4585589A3 (en) | 2008-12-03 | 2025-11-19 | The Scripps Research Institute | Stem cell cultures |
| CN102281761A (zh) * | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| WO2015127548A1 (en) | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US20180112180A1 (en) | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2018509459A (ja) | 2015-03-27 | 2018-04-05 | ナントクエスト インコーポレイテッド | がん治療薬との併用療法におけるｎｋ−９２細胞 |
| WO2016179283A1 (en) | 2015-05-05 | 2016-11-10 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| PT3294764T (pt) | 2015-05-15 | 2021-02-15 | Hope City | Composições de recetores de antigénios quiméricos |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| JP2019530470A (ja) * | 2016-08-05 | 2019-10-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδＦｏｘｐ３＋調節性Ｔ細胞のエクスビボ生成及びその治療的使用 |
| JP6987338B2 (ja) * | 2016-08-05 | 2021-12-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用 |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3068604A1 (en) | 2017-06-13 | 2018-12-20 | Fate Therapeutics, Inc. | Compositions and methods for inducing myeloid suppressive cells and use thereof |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
-
2017
- 2017-01-20 EP EP17742065.0A patent/EP3405568A4/en active Pending
- 2017-01-20 JP JP2018537803A patent/JP7653759B2/ja active Active
- 2017-01-20 US US16/071,460 patent/US11413309B2/en active Active
- 2017-01-20 WO PCT/US2017/014449 patent/WO2017127755A1/en not_active Ceased
-
2022
- 2022-07-08 US US17/861,042 patent/US12419870B2/en active Active
-
2023
- 2023-01-04 JP JP2023000071A patent/JP2023036919A/ja active Pending
-
2024
- 2024-12-16 JP JP2024219599A patent/JP2025038093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025038093A5 (https=) | ||
| JP2019502725A5 (https=) | ||
| US20240002797A1 (en) | Methods of cell culture for adoptive cell therapy | |
| Consentius et al. | Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo? | |
| CN109628406B (zh) | 一种治疗自身免疫疾病的间充质干细胞及其制备方法和应用 | |
| Morris et al. | Advances in the understanding of acute graft‐versus‐host disease | |
| ES2423993T3 (es) | Proteínas HLA-G y usos farmacéuticos de las mismas | |
| US20220380727A1 (en) | Generation of engineered regulatory t cells | |
| US20210061875A1 (en) | Compositions and methods for treating autoimmune disease | |
| CN109810947B (zh) | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 | |
| US20170216417A1 (en) | Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases | |
| EP1771196B1 (en) | Ccr ligands for stem cell homing | |
| WO2022049306A1 (en) | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof | |
| EP3873495B1 (en) | Methods and compositions for treatment of type 1 diabetes using fibroblasts as facilitators of islet engraftment | |
| JP5745419B2 (ja) | 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 | |
| CN114340642A (zh) | 用于胸腺再生和t细胞重建的组合物和方法 | |
| US20250353889A1 (en) | Fusion protein for maintenance of regulatory t-cells | |
| EP4320241A1 (en) | Compositions and methods for delivery of therapeutic agents to acceptor cells | |
| WO2024175738A1 (en) | Method for thymus regeneration | |
| US20250333697A1 (en) | Tethered interleukin-2 recombinant receptors and methods of use | |
| CN121586727A (zh) | 组成型细胞因子受体 | |
| CN119768508A (zh) | 重组细胞因子受体及其使用方法 | |
| Robertson et al. | Immunological advantages of living donor kidney transplantation |